Switch to:
More From Other Websites
Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally Dec 07 2016
Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT) Dec 07 2016
Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH) Dec 02 2016
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51 Dec 02 2016
5 Medical Tech Stocks You Should Be Investing In Dec 01 2016
Sarepta: UnitedHealth Induced Selloff a Buying Opportunity? Dec 01 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 30 2016
The 21st Century Cures Act Will Not Fix The FDA Nov 30 2016
Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says Nov 29 2016
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment Nov 21 2016
SAREPTA THERAPEUTICS, INC. Financials Nov 17 2016
3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise Nov 17 2016
How Donald Trump May Impact The FDA Nov 14 2016
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug Nov 11 2016
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High' Nov 11 2016
PTC Therapeutics Duchenne Drug Wins Extended European Approval Nov 11 2016
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other... Nov 08 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2016
Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare... Nov 04 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 02 2016
Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate... Oct 31 2016
Sarepta Therapeutics reports 3Q loss Oct 27 2016
Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate... Oct 25 2016
Sarepta partners with UK's Summit on Duchenne drugs Oct 04 2016
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement Oct 04 2016
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for... Oct 04 2016
BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal Oct 04 2016
Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and... Sep 29 2016
Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in... Sep 29 2016
Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in... Sep 29 2016
Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Sep 22 2016
Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Sep 22 2016
Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of... Sep 20 2016
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an... Sep 19 2016
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate... Jul 26 2016
Sarepta Therapeutics reports 2Q loss Jul 19 2016
Sarepta Therapeutics Announces Proposed Offering Jun 09 2016
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on... Jun 08 2016
FDA delay raises slim hope for muscular dystrophy drug May 25 2016
Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug... May 25 2016
CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule... May 14 2016
Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate... May 05 2016
Sarepta Therapeutics reports 1Q loss May 05 2016
Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of... May 05 2016
Muscular dystrophy drug falls short at high-stakes meeting Apr 25 2016
Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment... Apr 01 2016
Sarepta Therapeutics reports 4Q loss Feb 25 2016
Sarepta plunges on negative FDA drug review Jan 15 2016
Sarepta Therapeutics reports 3Q loss Nov 05 2015
Sarepta Therapeutics reports 2Q loss Aug 06 2015
BUZZ-Sarepta news lifts other muscular distrophy stocks May 20 2015
Sarepta Therapeutics reports 1Q loss May 07 2015
FDA panel to discuss Ebola vaccine development in May Mar 18 2015
Sarepta Therapeutics reports 4Q loss Feb 26 2015
Medicago wins contract to develop Ebola treatments Feb 24 2015
Sarepta Therapeutics tops 3Q profit forecasts Nov 06 2014
Sarepta tumbles on new delay for key drug Oct 27 2014
Ahead of the Bell: Sarepta Therapeutics climbs Oct 17 2014


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK